KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Cost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Clover Health Investments (CLOV) Shares Outstanding (Diluted Average) (2019 - 2025)

Historic Shares Outstanding (Diluted Average) for Clover Health Investments (CLOV) over the last 7 years, with Q3 2025 value amounting to $512.7 million.

  • Clover Health Investments' Shares Outstanding (Diluted Average) rose 460.31% to $512.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $512.7 million, marking a year-over-year increase of 460.31%. This contributed to the annual value of $490.0 million for FY2024, which is 162.65% up from last year.
  • Per Clover Health Investments' latest filing, its Shares Outstanding (Diluted Average) stood at $512.7 million for Q3 2025, which was up 460.31% from $509.0 million recorded in Q2 2025.
  • Clover Health Investments' Shares Outstanding (Diluted Average)'s 5-year high stood at $512.7 million during Q3 2025, with a 5-year trough of $376.2 million in Q1 2021.
  • Moreover, its 5-year median value for Shares Outstanding (Diluted Average) was $479.8 million (2023), whereas its average is $469.3 million.
  • Its Shares Outstanding (Diluted Average) has fluctuated over the past 5 years, first surged by 36557.12% in 2021, then surged by 67.64% in 2023.
  • Clover Health Investments' Shares Outstanding (Diluted Average) (Quarter) stood at $412.9 million in 2021, then increased by 15.34% to $476.2 million in 2022, then increased by 1.25% to $482.2 million in 2023, then rose by 1.63% to $490.0 million in 2024, then increased by 4.64% to $512.7 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $512.7 million for Q3 2025, versus $509.0 million for Q2 2025 and $497.1 million for Q1 2025.